Key result
Apixaban (60 tablets) was the most economically accessible direct oral anticoagulant for outpatient COVID-19 treatment, with an availability coefficient of 21.7 relative to the average wage and 66.1 relative to the living minimum.
Why the study?
What is the economic availability of direct oral anticoagulants for COVID-19 outpatient treatment?
What is the economic availability of direct oral anticoagulants for COVID-19 outpatient treatment?
Direct oral anticoagulants have low economic availability for COVID-19 outpatients, highlighting the need for government-funded drug programs.
Answers are grounded in this paper and cite their sources.
May inform cost-based DOAC selection in outpatient COVID-19; leaves open outcome and adherence impacts.
An assessment of the economic availability of direct oral anticoagulants for COVID-19 outpatient treatment was carried out. For each anticoagulant, the average cost of the package and treatment course were determined, the coefficients of availability in relation to the average wage and the minimum living wage were calculated. Based on the results of the study, an ABC analysis was carried out. The costs of dabigatran, apixaban and rivaroxaban were found to be in category A (high cost) in relation to the minimum living wage. The most accessible of the investigated anticoagulants is apixaban 5 mg in a package of 60 tablets, the coefficient of availability of this drug in relation to the average wage was 21.7, in relation to the living wage – 66.1. The low availability of anticoagulants for the course treatment of COVID-19 in outpatient settings justifies the need for the formation of drug programs for COVID-19 outpatient with at the expense of the federal budget.
No takes yet. Share an insight, caveat, or question.
Vinogradova et al. (2021) studied COVID-19. Direct oral anticoagulants (dabigatran, apixaban, rivaroxaban) was evaluated on Economic availability coefficient (cost relative to average wage and living minimum). Apixaban (60 tablets) was the most economically accessible direct oral anticoagulant for outpatient COVID-19 treatment, with an availability coefficient of 21.7 relative to the average wage and 66.1 relative to the living minimum.
Synapse has enriched 10 related papers. Consider them for comparative context: